Tell a Friend

  • captcha

Rheumatoid Arthritis

Currently Recruiting

Protocol

Inclusion Summary

Study 2

RA for ≥ 3 months

MTX therapy ≥ 3 months 15 to 25 mg/week

≥ 6 swollen joints and ≥ 6 tender joints

hsCRP ≥ 5 mg/L

Has at least one criteria:
a. ≥ 3 bone erosions on x-ray; or
b. ≥ 1 bone erosion and a positive rheumatoid factor (RF); or
c. ≥ 1 bone erosion and a positive anti-CCP autoantibody.

Subjects with prior exposure to at most one bDMARD

Ongoing – Recruitment Closed

Study 1

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Trial Registration Number: NCT01885078